April 06, 2020
The Partners of Citadel and Citadel Securities today announced $5 million of support to advance scientific relief initiatives at four New York City medical institutions at the forefront of New York’s COVID-19 response. The work will accelerate and scale cutting-edge solutions through the development of sophisticated testing, treatment and prevention capabilities. These initiatives represent the top scientific priorities for these leading medical institutions and have the potential to transform the local and national response to this pandemic, ultimately saving lives and positioning individuals to safely return to society and the workplace. This is particularly essential to enable healthcare workers to engage on the frontlines throughout the duration of the crisis.
The initiatives receiving this support include:
“The fortitude and compassion of our frontline responders is heroic. Doctors, nurses and countless others continue to relentlessly battle the virus and selflessly care for the sick, while our nation’s researchers pursue the science needed to ultimately lead us out of this pandemic,” said Ken Griffin, Founder and CEO of Citadel. “Collaboration and philanthropic support are essential to accelerate medical solutions and will be the difference in protecting as many lives as possible.”
Fast Facts On Initiatives Supported
Protect the frontlines through immunity-identifying serology efforts to inform safer redeployment of healthcare workers and others in New York and across the nation
“This pioneering serology and convalescent plasma program will allow us to further scale our efforts to help us save lives and is a potential game changer to help us turn the page on the virus,” said Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean, Icahn School of Medicine at Mount Sinai, and President for Academic Affairs, Mount Sinai Health System.
“Understanding the systemic effects of the virus will take time. We are in the epicenter of the outbreak right now, and being able to identify those with immunity will have immediate and significant impact,” said Robert I. Grossman, MD, Dean and CEO of NYU Langone Health.
Harness patient immunity to prevent infection and treat the most critically ill
“Teams of scientists and clinicians at Rockefeller have come together rapidly to develop use of plasma and specific virus-neutralizing antibodies from patients who have recovered from COVID-19,” says Richard P. Lifton, president of The Rockefeller University. “The immune therapies have the potential to treat ill and vulnerable patients and protect healthcare workers who are fighting the pandemic on the front lines.”
Scale rapid testing around the nation to test hundreds of thousands of people per day
Test promising prophylactic drug to prevent infection
“This generous gift will enable us to develop vital new approaches to protect our committed frontline healthcare workers and patients from contracting the disease. It will also power the creation of a rapid test to diagnose COVID-19, which is particularly important in the fight against this pandemic,” said Dr. Augustine M.K. Choi, the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine.
The partners of Citadel and Citadel Securities have deployed a multifaceted COVID-19 philanthropic program across the spectrum of relief initiatives from PPE and humanitarian aid, to supporting funding gaps to help those most affected, and accelerating scientific initiatives. The relief efforts began in mid-January and with this announcement they have provided over $16 million, including to: